Clinical and Experimental Reproductive Medicine

  • 제29권1호
  • /
  • Pages.45-56
  • /
  • 2002
  • /
  • 2233-8233(pISSN)
  • /
  • 2233-8241(eISSN)
대한생식의학회 (The Korean Society for Reproductive Medicine)
권호 표지

체외수정시술시 유전자 재조합 난포자극호르몬제의 효용성

The Efficacy of Recombinant Human Follicle Stimulating Hormone (rhFSH) in Human IVF-ET Program

  • 한국선 (성균관대학교 의과대학, 삼성제일병원 산부인과, 생식내분비학 불임분과) ;
  • 이홍복 (성균관대학교 의과대학, 삼성제일병원 산부인과, 생식내분비학 불임분과) ;
  • 송인옥 (성균관대학교 의과대학, 삼성제일병원 산부인과, 생식내분비학 불임분과) ;
  • 박용석 (성균관대학교 의과대학, 삼성제일병원 산부인과, 생식내분비학 불임분과) ;
  • 변혜경 (성균관대학교 의과대학, 삼성제일병원 산부인과, 생식내분비학 불임분과) ;
  • 전진현 (성균관대학교 의과대학, 삼성제일병원 산부인과, 생식내분비학 불임분과) ;
  • 궁미경 (성균관대학교 의과대학, 삼성제일병원 산부인과, 생식내분비학 불임분과)
  • Han, Kuk-Sun (Division of Reproductive Endocrinology & Infertility Department of Obstetrics and Gynecology, Samsung Cheil Hospital Sungkyunkwan University School of Medicine) ;
  • Lee, Hong-Bok (Division of Reproductive Endocrinology & Infertility Department of Obstetrics and Gynecology, Samsung Cheil Hospital Sungkyunkwan University School of Medicine) ;
  • Song, In-Ok (Division of Reproductive Endocrinology & Infertility Department of Obstetrics and Gynecology, Samsung Cheil Hospital Sungkyunkwan University School of Medicine) ;
  • Park, Yong-Seog (Division of Reproductive Endocrinology & Infertility Department of Obstetrics and Gynecology, Samsung Cheil Hospital Sungkyunkwan University School of Medicine) ;
  • Byun, Hye-Kyung (Division of Reproductive Endocrinology & Infertility Department of Obstetrics and Gynecology, Samsung Cheil Hospital Sungkyunkwan University School of Medicine) ;
  • Jun, Jin-Hyun (Division of Reproductive Endocrinology & Infertility Department of Obstetrics and Gynecology, Samsung Cheil Hospital Sungkyunkwan University School of Medicine) ;
  • Koong, Mi-Kyoung (Division of Reproductive Endocrinology & Infertility Department of Obstetrics and Gynecology, Samsung Cheil Hospital Sungkyunkwan University School of Medicine)
  • 발행 : 2002.03.30
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Objectives: Recently, recombinant FSH (rFSH) has been manufactured using a Chinese hamster ovary cell line transfected with the gene encoding human FSH. Both rFSH and urinary gonadotropin (uFSH) could be used for controlled ovarian hyperstimulation (COH). However, uFSH implies a number of disadvantages, such as batch-to-batch inconsistency, no absolute source control, dependence on large amounts of urine, low specific activity, and low purity. The purpose of this study was to evaluate the efficacy of rFSH in human IVF-ET program. Materials and Methods: A total of 508 infertile women was enrolled in this study. They are classified into rFSH group (n=177) or uFSH group (n=331), and all of them were matched by age and cause of infertility in same period. The $Puregon^{(R)}$ (Organon, Holland) was used as rFSH, and the Metrodin-$HP^{(R)}$ (Serono, Switzeland) and $Humegon^{(R)}$ (Organon, Holland) was used as uFSH. We subdivided the patients into three age groups. The outcomes of IVF-ET program were analyzed using the statistical package for social sciences (SPSS). Results: There was no significant differences in the level of estradiol on hCG injection day, the numbers of retrieved oocytes, matured oocytes, fertilized oocytes, transferred embryos, frozen embryos between the two groups. The total dose (IU) of gonadotropin for COH was significantly lower in the rFSH group compared to uFSH group ($1339{\pm}5491.1$ vs $2527.8{\pm}1075.2$ IU, p<0.001). Clinical pregnancy rate per embryo transfer in the rFSH group showed increasing tendency, compared to the uFSH group, but there was no statistical significance (35.2% vs 29.3%). Our results demonstrated that the relative efficiency of rFSH compared with uFSH is higher in older patients. Conclusions: The ovarian stimulatory effect and clinical outcome of recombinant FSH was similar to that of the urinary gonadotropin. The IVF-ET cycles with significantly lower dose of gonadotropin in rFSH group showed comparable results. Therefore, we suggest that recombinant FSH is more potent and effective than urinary gonadotropin.

키워드

참고문헌

  1. Templeton A, Morris JK. Reducing the risk of multiple births by transfer of two embryos after in vitro fertilization. N Engl J Moo 1998; 339: 573-7 https://doi.org/10.1056/NEJM199808273390901
  2. Waterstone J, Parsons J, Bolton V. Elective transfer of two embryos. Lancet 1991; 337: 975-6
  3. Nijs M, Geerts L, van Roosendaal E, Segal-Bertin G, Vanderzwalmen P, Schoysman R. Prevention of multiple pregnancies in an in vitro fertilization program. Fertil Steri1 1993; 59: 1245-50 https://doi.org/10.1016/S0015-0282(16)55984-6
  4. Staessen C, Janssenswillen C, Van den Abbeel E, Devroey P, Van Steirteghem AC. Avoidance of triplet pregnancies by elective transfer of two good quality embryos. Hum Reprod 1993; 8: 1650-3 https://doi.org/10.1093/oxfordjournals.humrep.a137907
  5. Stanger JD, Yovich JL. Reduced in-vitro fertilization of human oocytes from patients with raised basal luteinizing hormone levels during the follicular phase. Br J Obstet Gynaecol 1985; 92: 385-93 https://doi.org/10.1111/j.1471-0528.1985.tb01113.x
  6. Homburg R, Armar NA, Eshel A, Adams J, Jacobs HS. Influence of serum luteinising hormone concentrations on ovulation, conception and early pregnancy loss in polycystic ovarian syndrome. Br Med J 1988; 297: 1024-6 https://doi.org/10.1136/bmj.297.6655.1024
  7. Punnonen R, Ashorn R, Vilja P, Heinonen PK, Kujansuu E, Tuohimaa P. Spontaneous luteinizing hormone surge and cleavage of in vitro fertilized embryos. Fertil Steri1 1988; 49: 479-82 https://doi.org/10.1016/S0015-0282(16)59776-3
  8. Daya S, Gunby J, Hughes EG, Collins JA, Sagle MA. Follicle-stimulating hormone versus human menopausal gonadotropin for in vitro fertilization cycles: a meta-analysis. Ferril Steril 1995; 64: 347-54 https://doi.org/10.1016/S0015-0282(16)57734-6
  9. Howles CM, Loumaye E, Giroud D, Luyet G. Multiple follicular development and ovarian steroidogenesis following subcutaneous administration of a highly purified urinary FSH preparation in pituitary desensitized women undergoing IVF: a multicentre European phase III study. Hum Reprod 1994; 9: 424-30 https://doi.org/10.1093/oxfordjournals.humrep.a138522
  10. Wikland M, Borg J, Hamberger L, Svalander P. Simplification of IVF: minimal monitoring and the use of subcutaneous highly purified FSH administration for ovulation induction. Hum Reprod 1994; 9: 1430-6 https://doi.org/10.1093/oxfordjournals.humrep.a138724
  11. Chappel S, Kelton, C, Nugent N. Expression of human gonadotropins by recombinant DNA methods. In Genazzani, A.R and Petraaglia, F. (eds), Proceedings of the 3rd World Congress on Gynecological Endocrinology Parthenon Publishing Group, Carnforth, UK, 1992. p.179-184
  12. Olijve W, de Boer W, Mulders JW, van Wezenbeek PM. Molecular biology and biochemistry of human recombinant follicle stimulating hormone (Puregon). Mol Hum Reprod 1996; 2: 371-82 https://doi.org/10.1093/molehr/2.5.371
  13. Balen AH, Hayden CJ, Rutherford AJ. What are the clinical benefits of recombinant gonadotropins? Clinical efficacy of recombinant gonadotropins. Hum Reprod 1999; 14: 1411-7 https://doi.org/10.1093/humrep/14.6.1411
  14. Howles CM. Genetic engineering of human FSH (Gonal-F). Hum Reprod Update 1996; 2: 172-91 https://doi.org/10.1093/humupd/2.2.172
  15. Loumaye E. The control of endogenous secretion of LH by gonadotropin-releasing hormone agonists during ovarian hyperstimulation for in-vitro fertilization and embryo transfer. Hum Reprod 1990; 5: 357-76 https://doi.org/10.1093/oxfordjournals.humrep.a137105
  16. Recombinant Human FSH Product Development Group. Recombinant follicle stimulating hormone: development of the first biotechnology product for the treatment of infertility. Hum Reprod Update 1998; 4: 862-81 https://doi.org/10.1093/humupd/4.6.862
  17. Out HJ, Mannaerts BM, Driessen SG, Bennink HJ. A prospective, randomized, assessor-blind, multicentre study comparing recombinant and urinary follicle stimulating hormone (Puregon versus Metrodin) in in-vitro fertilization. Hum Reprod 1995; 10: 2534-40 https://doi.org/10.1093/oxfordjournals.humrep.a135740
  18. Redfearn A, Hughes EG, O'Connor M, Dolovich J. Delayed-type hypersensitivity to human gonadotropin: case report. Fertil Steri1 1995; 64: 855-6 https://doi.org/10.1016/S0015-0282(16)57865-0
  19. Albano C, Smitz J, Camus M, Bennink HC, Van Steirteghem AC, Devroey P. Pregnancy and birth in an in-vitro fertilization cycle after controlled ovarian stimulation in a woman with a history of allergic reaction to human menopausal gonadotropin. Hum Reprod 1996; 11: 1632-4 https://doi.org/10.1093/oxfordjournals.humrep.a019459
  20. Howles CM. Role of LH and FSH in ovarian function. Mol Cell Endocrinol 2000; 161: 25-30 https://doi.org/10.1016/S0303-7207(99)00219-1
  21. Levy DP, Navarro JM, Schattman GL, Davis OK, Rosenwaks Z. The role of LH in ovarian stimulation: exogenous LH: let's design the future. Hum Reprod 2000; 15: 2258-65 https://doi.org/10.1093/humrep/15.11.2258
  22. Bergh C, Howles CM, Borg K, Hamberger L, Josefsson B, Nilsson L, et al. Recombinant human follicle stimulating hormone (r-hFSH; Gonal-F) versus highly purified urinary FSH (Metrodin HP): results of a randomized comparative study in women undergoing assisted reproductive techniques. Hum Reprod 1997; 12: 2133-9 https://doi.org/10.1093/humrep/12.10.2133
  23. Hoomans EH, Andersen AN, Loft A, Leerentveld RA, van Kamp AA, Zech H. A prospective, randomized clinical trial comparing 150 IU recombinant follicle stimulating hormone (Puregon$\^circledR$) and 225 IU highly purified urinary follicle stimulating hormone (Metrodin-HP$\^circledR$) in a fixed-dose regimen in women undergoing ovarian stimulation. Hum Reprod 1999; 14: 2442-7 https://doi.org/10.1093/humrep/14.10.2442
  24. Frydman R, Howles CM, Truong F. A double-blind, randomized study to compare recombinant human follicle stimulating hormone (FSH; Gonal-F) with highly purified urinary FSH (Metrodin-HP) in women undergoing assisted reproductive techniques including intracytoplasmic sperm injection. The French Multicentre Trialists. Hum Reprod 2000; 15: 520-5 https://doi.org/10.1093/humrep/15.3.520
  25. Lenton E, Soltan A, Hewitt J, Thomson A, Davies W, Ashraf N, et al. Induction of ovulation in women undergoing assisted reproductive techniques: recombinant human FSH (follitropin alpha) versus highly purified urinary FSH (urofollitropin HP). Hum Reprod 2000; 15: 1021-7 https://doi.org/10.1093/humrep/15.5.1021
  26. Camier B, Avril C, Cohen J. A multicentre, prospective, randomised study to compare a low dose protocol versus conventional administration of recombinant human follicle stimulating hormone (Gonal-F$\^circledR$) in normo-responder women undergoing IVF/ICSI (abstract) 14th Annual Meeting of the European Society of Human Reproduction and Embryology Gothenburg, Sweden, 1998 June. Hum Reprod 13 (Abstract BK.1), P-058
  27. Brinsden P, Akagbosu F, Gibbons LM, Lancaster S, Gourdon D, Engrand P, et al. A comparison of the efficacy and tolerability of two recombinant human follicle-stimulating hormone preparations in patients undergoing in vitro fertilization-embryo transfer. Fertil Steril 2000; 73: 114-6 https://doi.org/10.1016/S0015-0282(99)00450-1
  28. Khalaf Y, Taylor A, Pettigrew R. The relative clinical efficacy of recombinant follicle stimulating hormone to the highly purified urinary preparation. Assist Reprod Rev In press 2000
  29. Mannaerts BM, Rombout F, Out HJ, Coelingh Bennink H. Clinical profiling of recombinant follicle stimulating hormone (rFSH; Puregon): relationship between serum FSH and efficacy. Hum Reprod Update 1996; 2: 153-61 https://doi.org/10.1093/humupd/2.2.153
  30. Ravhon A, Lavery S, Aurell R, Trew G, Margara R, Winston R. Clinical experience with recombinant follicle-stimulating hormone (FSH) and urinary FSH: a retrospective case- controlled analysis. Fertil Steril 2001; 75: 920-5 https://doi.org/10.1016/S0015-0282(01)01684-3
  31. Bennink HJTC, Fauser BCJM, Out HJ. Recombinant follicle-stimulating hormone (FSH; Puregon) is more efficient than urinary FSH (Metrodin) in women with clomiphene citrate-resistant, normogonadotropic, chronic anovulation: a prospective, multicenter, assessor-blind, randomized, clinical trial. Fertil Steril 1998; 69: 19-25 https://doi.org/10.1016/S0015-0282(97)00423-8
  32. Recombinant Human FSH Study Group. Clinical assessment of recombinant human follicle-stimulating hormone in stimulating ovarian follicular development before in vitro fertilization. Fertil Steril 1995; 63: 77-86 https://doi.org/10.1016/S0015-0282(16)57300-2
  33. Jansen CA, van Os HC, Out HJ, Coelingh Bennink HJ. A prospective randomized clinical trial comparing recombinant follicle stimulating hormone (Puregon) and human menopausal gonadotropins (Humegon) in non-down-regulated in-vitro fertilization patients. Hum Reprod 1998; 13: 2995-9 https://doi.org/10.1093/humrep/13.11.2995
  34. Hedon B, Out HJ, Hugues JN, Camier B, Cohen J, Lopes P, et al. Efficacy and safety of recombinant follicle stimulating hormone (Puregon) in infertile women pituitary-suppressed with triptorelin undergoing in-vitro fertilization: a prospective, randomized, assessor-blind, multicentre trial. Hum Reprod 1995; 10: 3102-6 https://doi.org/10.1093/oxfordjournals.humrep.a135866
  35. Yarali H, Bukulmez O, Gurgan T. Urinary follicle-stimulating hormone (FSH) versus recombinant FSH in clomiphene citrate-resistant, normogonado-tropic, chronic anovulation: a prospective randomized study. Fertil Steril 1999; 72: 276-81 https://doi.org/10.1016/S0015-0282(99)00209-5
  36. Delvigne A, Dubois M, Battheu B, Bassil S, Meuleman C, De Sutter P, et al. The ovarian hyperstimulation syndrome in in-vitro fertilization: a Belgian multicentric study. II. Multiple discriminant analysis for risk prediction. Hum Reprod 1993; 8: 1361-6
  37. Out HJ, Braat DD, Lintsen BM, Gurgan T, BukuImez O, Gokmen O, et al. Increasing the daily dose of recombinant follicle stimulating hormone (Puregon) does not compensate for the age-related decline in retrievable oocytes after ovarian stimulation. Hum Reprod 2000; 15: 29-35 https://doi.org/10.1093/humrep/15.1.29
  38. Out HJ, Lindenberg S, Mikkelsen AL, Eldar-Geva T, Healy DL, Leader A, et al. A prospective, randomized, double-blind clinical trial to study the efficacy and efficiency of a fixed dose of recombinant follicle stimulating hormone (Puregon) in women undergoing ovarian stimulation. Hum Reprod 1999; 14: 622-7 https://doi.org/10.1093/humrep/14.3.622
  39. Raga F, Bonilla-Musoles F, Casan EM, Bonilla F. Recombinant follicle stimulating hormone stimulation in poor responders with normal basal concentrations of follicle stimulating hormone and oestradiol: improved reproductive outcome. Hum Reprod 1999; 14: 1431-4 https://doi.org/10.1093/humrep/14.6.1431
  40. De Placido G, Alviggi C, Mollo A, Strina I, Varricchio MT, Molis M. Recombinant follicle stimulating hormone is effective in poor responders to highly purified follicle stimulating hormone. Hum Reprod 2000; 15: 17-20 https://doi.org/10.1093/humrep/15.1.17
  41. Aboulghar MA, Mansour RT, Serour GI, Amin YM, Kamal A. Prospective controlled randomized study of in vitro fertilization versus intracytoplasmic sperm injection in the treatment of tubal factor infertility with normal semen parameters. Fertil Steril 1996; 66: 753-6 https://doi.org/10.1016/S0015-0282(16)58630-0
  42. Staessen C, Camus M, Clasen K, De Vos A, Van Steirteghem A. Conventional in-vitro fertilization versus intracytoplasmic sperm injection in sibling oocytes from couples with tubal infertility and normozoospermic semen. Hum Reprod 1999; 14: 2474-9 https://doi.org/10.1093/humrep/14.10.2474
  43. Bukulmez O, Yarali H, Yucel A, Sari T, Gurgan T. Intracytoplasmic sperm injection versus in vitro fertilization for patients with a tubal factor as their sole cause of infertility: a prospective, randomized trial. Fertil Steril 2000; 73: 38-42 https://doi.org/10.1016/S0015-0282(99)00449-5
  44. Horsman G, Talbot JA, McLoughlin JD, Lambert A, Robertson WR. A biological, immunological and physico-chemical comparison of the current clinical batches of the recombinant FSH preparations Gonal-F and Puregon. Hum Reprod 2000; 15: 1898-902 https://doi.org/10.1093/humrep/15.9.1898
  45. Tulppala M, Aho M, Tuuri T, Vilska S, Foudila T, Hakala-Ala-Pietila T, et al. Comparison of two recombinant follicle-stimulating hormone preparations in in-vitro fertilization: a randomized clinical study. Hum Reprod 1999; 14: 2709-15 https://doi.org/10.1093/humrep/14.11.2709